COVID-19-associated neutrophilia

For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here

WikiDoc Resources for COVID-19-associated neutrophilia
Articles
Most recent articles on COVID-19-associated neutrophilia Most cited articles on COVID-19-associated neutrophilia Review articles on COVID-19-associated neutrophilia Articles on COVID-19-associated neutrophilia in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on COVID-19-associated neutrophilia Images of COVID-19-associated neutrophilia Photos of COVID-19-associated neutrophilia Podcasts & MP3s on COVID-19-associated neutrophilia Videos on COVID-19-associated neutrophilia
Evidence Based Medicine
Cochrane Collaboration on COVID-19-associated neutrophilia Bandolier on COVID-19-associated neutrophilia TRIP on COVID-19-associated neutrophilia
Clinical Trials
Ongoing Trials on COVID-19-associated neutrophilia at Clinical Trials.gov Trial results on COVID-19-associated neutrophilia Clinical Trials on COVID-19-associated neutrophilia at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on COVID-19-associated neutrophilia NICE Guidance on COVID-19-associated neutrophilia NHS PRODIGY Guidance FDA on COVID-19-associated neutrophilia CDC on COVID-19-associated neutrophilia
Books
Books on COVID-19-associated neutrophilia
News
COVID-19-associated neutrophilia in the news Be alerted to news on COVID-19-associated neutrophilia News trends on COVID-19-associated neutrophilia
Commentary
Blogs on COVID-19-associated neutrophilia
Definitions
Definitions of COVID-19-associated neutrophilia
Patient Resources / Community
Patient resources on COVID-19-associated neutrophilia Discussion groups on COVID-19-associated neutrophilia Patient Handouts on COVID-19-associated neutrophilia Directions to Hospitals Treating COVID-19-associated neutrophilia Risk calculators and risk factors for COVID-19-associated neutrophilia
Healthcare Provider Resources
Symptoms of COVID-19-associated neutrophilia Causes & Risk Factors for COVID-19-associated neutrophilia Diagnostic studies for COVID-19-associated neutrophilia Treatment of COVID-19-associated neutrophilia
Continuing Medical Education (CME)
CME Programs on COVID-19-associated neutrophilia
International
COVID-19-associated neutrophilia en Espanol COVID-19-associated neutrophilia en Francais
Business
COVID-19-associated neutrophilia in the Marketplace Patents on COVID-19-associated neutrophilia
Experimental / Informatics
List of terms related to COVID-19-associated neutrophilia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Oluwabusola Fausat Adogba, MD

Synonyms and keywords:

Overview

Coronavirus disease 2019 (COVID-19) has been considered as a global pandemic since its first emergence in Wuhan,China.On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic.There is no established system for the classification regarding COVID-19 associated neutrophilia.Research suggests COVID-19 associated neutrophilia could be the cause of the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS). It can be linked to the Neutrophil Extracellular Traps (NETs). Acute Respiratory Distress Syndrome (ARDS), pulmonary inflammation, thick mucus secretions in the airways, extensive lung damage, and blood clots are suggested to be as a result of the action of Neutrophils. When neutrophils detect pathogens, they can expel their DNA in a web laced with toxic enzymes (called a NET- Neutrophil Extracellular Trap) to attack them.These NETs capture and digest the unwanted pathogen but in cases of ARDS (Covid-19 manifestation) they cause damage to the lungs and other organs. People of any age with certain underlying medical conditions are at increased risk for severe illness from COVID-19.Recent studies have shown the association of a high Neutrophil-to-lymphocyte ratio (NLR) to severe forms of COVID-19 disease.

Historical Perspective

• Coronavirus disease 2019 (COVID-19) has been considered as a global pandemic since its first emergence in Wuhan,China.

• On March 12, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic.

Classification

There is no established system for the classification regarding COVID-19 associated neutrophilia.

Pathophysiology

• Study suggests COVID-19 associated neutrophilia could be the cause of the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS). It can be linked to the Neutrophil Extracellular Traps (NETs).
• Acute Respiratory Distress Syndrome (ARDS), pulmonary inflammation, thick mucus secretions in the airways, extensive lung damage, and blood clots are suggested to be as a result of the action of Neutrophils. When neutrophils detect pathogens, they can expel their DNA in a web laced with toxic enzymes (called a NET- Neutrophil Extracellular Trap) to attack them.
• These NETs capture and digest the unwanted pathogen but in cases of ARDS (Covid-19 manifestation) they cause damage to the lungs and other organs.

Causes

The SARS-CoV-2 COVID-19 viral infection is the known cause of neutrophilia associated disease in infected patients.

Differentiating COVID-19 related Neutrophilia from other Diseases

COVID-19 related Neutrophilia starts acutely in the course of the disease, with other manifestations of the disease. Neutrophilia can occur in the following conditions:

• Acute infections
  • Bacteria - Staphyloccoci, Streptococci, Meningococci
  • Virus- Varicella, Herpes zoster
  • Fungi- Candida, Coccidioides
• Non-infectious inflammation
  • Rheumatic fever
  • Acute glomerulonephritis
  • Collagen-Vascular diseases
  • Diabetic ketoacidosis

Epidemiology and Demographics

• The incidence of the Coronavirus Disease 2019 (COVID-19) as of June 28, 2020 is approximately 9,843,073 cases worldwide with 495,760 deaths.
• Patients of all age groups may develop COVID-19. However, the elderly population and immunocompromised individuals are more likely to develop severe cases of COVID-19.

Risk Factors

People of any age with certain underlying medical conditions are at increased risk for severe illness from COVID-19. These medical conditions include:

• Chronic kidney disease
• Chronic obstructive pulmonary disease
• Immunocompromised state (weakened immune system) from solid organ transplant
• Obesity (body mass index [BMI] of 30 or higher)
• Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
• Sickle cell disease
• Type 2 diabetes mellitus

Screening

• A high Neutrophil-to-lymphocyte ratio has been linked to ICU admission. A routine Complete blood count (CBC) test should be done in COVID-19 patients for early detection.

Natural History, Complications, and Prognosis

• Common hematologic complications of coronavirus include lymphopenia, neutrophilia and thrombocytosis.
• Although the pathogenesis of the cytokine storm associated with Neutrophilia in COVID-19 patients is unclear. It has however been associated with poor outcomes in patients. The neutrophil-to-lymphocyte ratio has been identified as an independent risk factor for severe disease in COVID-19 patients.

Diagnosis

Diagnostic study of Choice

• Peripheral white blood cell count on a CBC with differential test
• Neutrophil-lymphocyte ratio
• C-reactive protein
• Erythrocyte sedimentation rate

History and Symptoms

Neutrophilia as a result of COVID-19 can present with different symptoms. People with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms may have COVID-19:

• Fever or chills
• Cough
• Shortness of breath or difficulty breathing
• Fatigue
• Muscle or body aches
• Headache
• New loss of taste or smell
• Sore throat
• Congestion or runny nose
• Nausea or vomiting
• Diarrhea

Physical Examination

• There are no physical findings associated with neutrophilia.

Neutrophilia as an indicator for severe disease

• Recent studies have shown the association of a high Neutrophil-to-lymphocyte ratio (NLR) to severe forms of COVID-19 disease.
• NLR >4 on admission has been linked to ICU admission.
• COVID-19 patients with severe disease presentation had a higher NLR on admission compared to patients with a milder COVID-19 disease presentation.

Electrocardiogram

There are no ECG findings associated with COVID-19 associated neutrophilia

X-ray

There are no X-ray findings associated with COVID-19 associated neutrophilia.

Echocardiography or Ultrasound

There are no echocardiography or ultrasound findings associated with COVID-19 associated neutrophilia.

CT Scan

There are no CT scan findings associated with COVID-19 associated neutrophilia.

MRI

There are no MRI findings associated with COVID-19 associated neutrophilia.

Other imaging findings

There are no other imaging findings associated with COVID-19 associated neutrophilia.

Other Diagnostic studies

• Bone marrow biopsy, although not recommended may be helpful if there is suspicion of other disorders that can cause neutrophilia , but there is not enough evidence to support bone marrow biopsy in COVID-19 patients.

Treatment

Medical therapy

Immune-Based Therapy:

• There are insufficient data to recommend either for or against the use of COVID-19 convalescent plasma or SARS-CoV-2 immune globulins for the treatment of COVID-19.

The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of non-SARS-CoV-2-specific intravenous immune globulin (IVIG) for the treatment of COVID-19, except in the context of a clinical trial. This should not preclude the use of IVIG when it is otherwise indicated for the treatment of complications that arise during the course of COVID-19.

• There are insufficient data to recommend either for or against the use of the following agents for the treatment of COVID-19:
  • Interleukin-1 inhibitors (e.g., anakinra)
  • Interleukin-6 inhibitors (e.g., sarilumab, siltuximab, tocilizumab)

Except in the context of a clinical trial, the Panel recommends against the use of other immunomodulators, such as: Interferons, because of the lack of efficacy in treatment of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) and toxicity. Janus kinase inhibitors (e.g., baricitinib), because of their broad immunosuppressive effect.

References

Template:WikiDoc Sources